应用STE/STQ技术评估慢性乙型肝炎患者肝纤维化程度效能研究*

doi:10.3969/j.issn.1672-5069.2024.01.006

摘要/Abstract

摘要： 目的探讨采用声触诊弹性成像(STE)和声触诊弹性测量(STQ)技术评估慢性乙型肝炎(CHB)患者肝纤维化程度的效能。方法 2020年1月～2022年12月我院收治的CHB患者126例,常规进行肝穿刺活检,将组织病理学诊断为F0期和F1期肝纤维化定义为非显著性肝纤维化,将F2期、F3期和F4期肝纤维化定义为显著性肝纤维化。使用STE和STQ技术行肝硬度检测(LSM),常规检测血生化和血常规,计算肝纤维化-4因子指数(FIB-4)和天冬氨酸氨基转移酶/血小板比率指数(APRI),应用Logistic回归分析影响肝纤维化程度的因素,应用受试者工作特征曲线下面积(AUC)评估STE和STQ技术诊断CHB患者显著性肝纤维化的效能。结果在126例CHB患者中,肝组织病理学检查显示F0期肝纤维化7例、F1期38例、F2期42例、F3期34例和F4期5例,即非显著性肝纤维化组45例和显著性肝纤维化组81例;显著性肝纤维化组LSM_STE、LSM_STQ、FIB-4和APRI分别为(13.6±3.4)kPa、(16.8±4.5)kPa、(2.0±0.5)和(1.1±0.3),均显著高于非显著性肝纤维化组【分别为(9.2±2.3)kPa、(10.7±3.1)kPa、(1.4±0.3)和(0.7±0.2),P＜0.05】;多因素Logistic回归分析显示,LSM_STE、LSM_STQ、FIB-4和APRI为影响CHB患者发生显著性肝纤维化的独立因素(P＜0.05);ROC曲线分析显示,LSM_STE和LSM_STQ诊断CHB患者显著性肝纤维化的截断点、AUC、敏感度和特异度分别为11.6 kPa、0.867、76.5%和86.7%,和14.8 kPa、0.856、70.4%和86.7%,均显著优于FIB-4(1.8、0.753、60.5%和80.0%,P＜0.05)或APRI(1.0、0.736、59.3%和77.8%,P＜0.05)诊断。结论采用STE和STQ技术检测肝脏硬度能有效评估CHB患者肝纤维化程度,可为临床诊断和治疗提供无创诊断手段,具有良好的应用价值,值得临床进一步研究。

关键词: 慢性乙型肝炎, 肝纤维化, 声触诊弹性成像, 声触诊弹性测量, 诊断

Abstract: Objective The aim of this study was to explore the evaluation of liver fibrosis by liver stiffness measurement (LSM) revealed by sound touch elastography (STE) and sound touch quantify (STQ) in patients with chronic hepatitis B (CHB). Methods 126 patients with CHB were enrolled in our hospital between January 2020 and December 2022, and all underwent routine liver biopsy. The non-significant liver fibrosis (NSLF) was defined as liver fibrosis at stages F0 and F1, and the significant liver fibrosis (SLF) was defined as liver fibrosis at stages F2, F3 and F4. The LSM was detected by STE and STQ. The blood routine and serum biochemical parameters were routinely obtained, and the fibrosis index based on the four factors (FIB-4) and aspartate aminotransferase /platelet ratio index (APRI) were calculated. The influencing factors of liver fibrosis severity were analyzed by multivariate Logistic regression analysis, and the diagnostic efficacy for the severity of liver fibrosis was evaluated by the area under receiver operating characteristic (ROC) curve (AUC). Results Out of the 126 patients with CHB, the liver histopathological examination showed liver fibrosis at stage F0 in 7 cases, F1 in 38 cases, F2 in 42 cases, F3 in 34 cases and F4 in 5 cases, e.g., the NSLF in 45 cases and SLF in 81 cases; the LSM_STE, LSM_STQ, FIB-4 and APRI in patients with SLF were (13.6±3.4)kPa,(16.8±4.5)kPa, (2.0±0.5) and (1.1±0.3), all significantly greater than [(9.2±2.3) kPa, (10.7±3.1)kPa, (1.4±0.3) and (0.7±0.2), respectively, P＜0.05] in patients with NSLF; the multivariate Logistic regression analysis showed that the LSM_STE, LSM_STQ, FIB-4 and APRI were all the independent risk factors impacting the existence of SLF in patients with CHB (P＜0.05); the ROC analysis demonstrated that the cut-off-value, the AUCs, the sensitivity (Se) and specificity(Sp) by LSM_STE and LSM_STQ in predicting the occurrence of SLF in patients with CHB were 11.6 kPa, 0.867, 76.5% and 86.7%, and 14.8 kPa, 0.856, 70.4% and 86.7%, all much superior to 1.8, 0.753, 60.5% and 80.0% (P＜0.05) by FIB-4 or 1.0, 0.736, 59.3% and 77.8% (P＜0.05) by APRI. Conclusion The detection of SLM obtained by STE and STQ might help evaluate the severity of liver fibrosis in patients with CHB, and warrants further clinical investigation.

Key words: Hepatitis B, Liver fibrosis, Liver stiffness measurement, Sound touch elastography, Sound touch quantify, Diagnosis

李凯, 石波, 程序, 赵凯. 应用STE/STQ技术评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 20-23.

Li Kai, Shi Bo, Cheng Xu, et al. Assessment of liver fibrosis with liver stiffness measurement obtained by STE/STQ in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2024, 27(1): 20-23.

参考文献

[1] 杨艳, 刘婷, 戴琳, 等. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析. 实用肝脏病杂志, 2022, 25(2):183-186.
[2] Lee SW, Choi J, Kim SU, et al. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol, 2021, 27(3):402-412.
[3] Nam H, Lee SW, Kwon JH, et al. Prediction of hepatocellular carcinoma by on-therapy response of noninvasive fibrosis markers in chronic hepatitis B. Am J Gastroenterol, 2021, 116(8):1657-1666.
[4] Tseng TC, Choi J, Nguyen MH, et al. One-year fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int, 2021, 15(1):105-113.
[5] Öznur M, Topçu B, Çelikkol A. Predictive value of noninvasive indices in chronic hepatitis B virus-related fibrosis. Eur J Gastroenterol Hepatol, 2021, 33(4):577-582.
[6] Dong B, Huang S, Chang J, et al. Comparison of sound touch elastography, sound touch quantify, and 4 serum fibrosis indexes for the diagnosis of liver fibrosis in patients with chronic hepatitis B. Ultrasound Q, 2021, 37(2):123-128.
[7] Dong BT, Huang S, Lyu GR, et al. Assessment of liver fibrosis with liver and spleen stiffness measured by sound touch elastography, serum fibrosis markers in patients with chronic hepatitis B. J Dig Dis, 2021, 22(6):342-350.
[8] 中华医学会感染病学分会和肝病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):9-32.
[9] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 1996, 24(2):289-293.
[10] Mak LY, Hui RW, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol, 2020, 73(4):800-806.
[11] Raihan R, Akbar SMF, Al Mahtab M, et al. Increased proinflammatory cytokine production by chronic hepatitis B patients with mutant hepatitis B virus: plausible mechanisms underlying severe liver diseases in these patients. Viral Immunol, 2020, 33(7):530-534.
[12] Catania R, Furlan A, Smith AD, et al. Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease. Eur Radiol, 2021, 31(1):256-263.
[13] Zehra M, Curry JC, Pillai SS, et al. Elucidating potential profibrotic mechanisms of emerging biomarkers for early prognosis of hepatic fibrosis. Int J Mol Sci, 2020, 21(13):4737.
[14] Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut, 2020, 69(7):1343-1352.
[15] Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients withNAFLD: an individual patient data meta-analysis. Gut, 2022, 71(5):1006-1019.
[16] 何舒丽, 李双杰, 刘敏, 等. 瞬时弹性成像技术、APRI及FIB-4对儿童非酒精性脂肪性肝病肝纤维化诊断价值的研究. 中华肝脏病杂志, 2022, 30(1):81-86.
[17] Galina P, Alexopoulou E, Mentessidou A, et al. Diagnostic accuracy of two-dimensional shear wave elastography in detecting hepatic fibrosis in children with autoimmune hepatitis, biliary atresia and other chronic liver diseases. Pediatr Radiol, 2021, 51(8):1358-1368.
[18] 董丙田, 黄枢, 常建东, 等. 声触诊弹性成像与4项血清纤维化指标评估慢性乙型肝炎肝纤维化的效能比较. 中华肝脏病杂志, 2020, 28(3):269-272.
[19] Gatos I, Drazinos P, Yarmenitis S, et al. Comparison of sound touch elastography, shear wave elastography and vibration-controlled transient elastography in chronic liver disease assessment using liver biopsy as the "reference standard". Ultrasound Med Biol, 2020, 46(4):959-971.
[20] Yang L, Ling W, He D, et al. Shear wave-based sound touch elastography in liver fibrosis assessment for patients with autoimmune liver diseases. Quant Imaging Med Surg, 2021, 11(4):1532-1542.
[21] Metwally K, Elsabaawy M, Abdel-Samiee M, et al. FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients. Clin Exp Hepatol, 2020, 6(4):335-338.
[22] Ramzy I, Fouad R, Salama R, et al. Evaluation of red cell distribution width to platelet ratio as a novel non-invasive index for predicting hepatic fibrosis in patients with chronic hepatitis C. Arab J Gastroenterol, 2021, 22(1):6-11.

应用STE/STQ技术评估慢性乙型肝炎患者肝纤维化程度效能研究^*

Assessment of liver fibrosis with liver stiffness measurement obtained by STE/STQ in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	虞珊珊, 张业婷, 王元鹏, 袁静文, 肖立. 慢性乙型肝炎患者血清MMP-1、MMP-2、TIMP-1和HIF-1α变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 329-332.
[2]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[3]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[4]	尹丹丹, 张瑞珏, 王帅, 代爱军, 周正, 张帆. 30岁以下血清ALT正常的成人慢性HBV感染者肝组织学变化研究[J]. 实用肝脏病杂志, 2024, 27(3): 341-344.
[5]	彭玉静, 郭航, 陈俊光. 应用超声评分联合STE/STQ定量检测肝脏硬度评估慢性乙型肝炎患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 345-348.
[6]	程艳洁, 王鹏飞, 李峻. 水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 349-352.
[7]	曹焱芬, 邹昊轩, 谢艳. 体检人群血浆致动脉粥样硬化指数诊断代谢相关脂肪性肝病效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 361-365.
[8]	高萍, 高学松, 张亦瑾, 孙磊, 刘楠, 李洪杰, 刘亚平, 高丽丽, 段雪飞. 8例血色病患者临床与基因突变特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 386-389.
[9]	董旭, 秦阳华, 陈怡, 许明晓, 葛玲玲, 徐圣, 廖威. 预后营养指数联合全身免疫炎症指数评估乙型肝炎相关慢加急性肝衰竭患者预后临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 390-393.
[10]	蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东. 基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(3): 406-409.
[11]	白萍, 王汉, 刘芮, 曾智萍. 多层螺旋CT与磁共振LAVA增强扫描诊断肝内占位性病变性质效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 422-425.
[12]	梅文娟, 李新, 张昊月. 超声造影时间-强度曲线相关参数鉴别诊断肝细胞癌与转移性肝癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 430-433.
[13]	王倩文, 胡琳琳, 徐运军. 动态增强MRI联合血清SPINK1水平诊断原发性肝癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 442-445.
[14]	师玉, 孟令辉, 王禄马. 肝内胆管细胞癌增强CT扫描特征及其诊断价值分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 446-449.
[15]	陈爱娥, 彭向前, 陈利娜. 术前多层螺旋CT检查胆囊结石合并胆囊炎患者对术式选择的指导意义分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 466-469.